The PMCPA advertises in the medical and pharmaceutical press
brief details of all cases where companies are ruled in breach of Clause 2 of the Code, are required to issue a corrective statement or are the subject of a public reprimand.
All advertisements and all public reprimands issued within the last twelve months can be found below. The full advertisements that appeared in the press are available to view as attachments.
To read the full case report from any of the cases mentioned in this section, go to completed cases and search by the case number(s) listed at the end of the advertisements.
Click here for information on other available sanctions.
Grünenthal Ltd and Vifor Pharma UK Limited named in advertisements for breaches of the ABPI Code of Practice
July 2012
Grünenthal Ltd and Vifor Pharma UK Limited have each breached Clause 2 of the ABPI Code of Practice and are the subjects of advertisements in the medical, pharmaceutical and nursing press.
Boehringer Ingelheim Limited named in advertisements for breaches of the ABPI Code of Practice
February 2012
Boehringer Ingelheim Limited has breached Clause 2 of the ABPI Code of Practice and is the subject of advertisements in the medical, pharmaceutical and nursing press.
Boehringer Ingelheim Limited named in advertisements for breaches of the ABPI Code of Practice
November 2011
Boehringer Ingelheim Limited has breached Clause 2 of the ABPI Code of Practice and is the subject of advertisements in the medical, pharmaceutical and nursing press.
Bayer Healthcare named in advertisements for breaches of the ABPI Code of Practice
August 2011
Bayer Healthcare has breached Clause 2 of the ABPI Code of Practice and is the subject of advertisements in the medical, pharmaceutical and nursing press.
Chiesi Limited, Eli Lilly and Company Limited, Bayer Healthcare and Bayer Schering Pharma
May 2011
Chiesi Limited, Eli Lilly and Company Limited and Bayer Healthcare have each breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon,and/or reduced confidence in, the pharmaceutical industry. Bayer Schering Pharma has breached the Code and has been publicly reprimanded.To highlight these breaches, all are the subject of advertisements in the medical, pharmaceutical and nursing press.
Allergan Limited and Cephalon (UK) Limited
February 2011
Allergan Limited and Cephalon (UK) Limited have each breached the ABPI Code of Practice for the Pharmaceutical Industry. To highlight these breaches, both are the subject of advertisements in the medical, pharmaceutical and nursing press.
Novo Nordisk Limited, Eli Lilly and Company Limited, Grünenthal Ltd and Napp Pharmaceuticals Limited
November 2010
Novo Nordisk Limited, Eli Lilly and Company Limited, Grünenthal Ltd and Napp Pharmaceuticals Limited have each breached the ABPI Code of Practice for the Pharmaceutical Industry. To highlight these breaches, all are the subject of advertisements in the medical, pharmaceutical and nursing press. In addition, Novo Nordisk has been publicly reprimanded in relation to two matters.
ProStrakan Group plc, Cephalon UK Limited and GlaxoSmithKline Consumer Healthcare named in advertisements for breaches of the AB
August 2010
Astellas Pharma Ltd
Astellas Pharma Ltd has breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in, the pharmaceutical industry.
Solvay Healthcare Limited, Pfizer Limited and Procter & Gamble Pharmaceuticals UK, Limited
Solvay Healthcare Limited, Pfizer Limited and Procter & Gamble Pharmaceuticals UK, Limited have each breached The Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry. To highlight these breaches, all are the subjects of advertisements in the medical, pharmaceutical and nursing press. In addition Solvay has been publicly reprimanded.
